Literature DB >> 17293196

Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study).

Moeen Abedin1, Torbjørn Omland, Thor Ueland, Amit Khera, Pål Aukrust, Sabina A Murphy, Tulika Jain, Ugis Gruntmanis, Darren K McGuire, James A de Lemos.   

Abstract

Circulating osteoprotegerin (OPG) has been shown to be elevated in patients with vascular disease. The role of OPG as a biomarker for atherosclerosis in a large, unselected population is not well known. Plasma OPG levels were measured in 3,386 subjects in the Dallas Heart Study, a multiethnic, population-based probability sample of adults aged 30 to 65 years. Coronary artery calcium (CAC) was measured by electron beam computed tomography. Aortic plaque was assessed by magnetic resonance imaging. Multivariable logistic regression was used to assess associations among OPG, cardiovascular risk factors, CAC, and aortic plaque. Age, female gender, black race, smoking, personal and family history of coronary artery disease (CAD), diabetes mellitus, hyperlipidemia, CAC, and aortic plaque were significantly associated with higher plasma OPG levels (p <0.01) in univariable analyses. The prevalence of CAC and aortic plaque increased across OPG quartiles (p <0.001 for each). An OPG level in the fourth quartile was independently associated with CAC (RR 1.39, 95% confidence interval 1.01 to 1.93) and aortic plaque (RR 1.42, 95% confidence interval 1.09 to 1.86) after adjustment for age, gender, smoking, diabetes, hyperlipidemia, and family history of premature CAD. In conclusion, plasma OPG is independently associated with CAC and aortic plaque in an unselected population, suggesting it may be a novel biomarker for atherosclerosis in humans.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17293196     DOI: 10.1016/j.amjcard.2006.08.064

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  59 in total

Review 1.  The bone-vascular axis in chronic kidney disease.

Authors:  Linda Demer; Yin Tintut
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-07       Impact factor: 2.894

2.  Associations of osteoprotegerin with coronary artery calcification among women with systemic lupus erythematosus and healthy controls.

Authors:  I G Poornima; K Shields; L H Kuller; S M Manzi; R Ramsey-Goldman; C Richardson; E Rhew; D D Dunlop; J Song; D Edmundowicz; G T Kondos; J J Carr; C B Langman; H Price; A H Chung; L B Santelices; R H Mackey
Journal:  Lupus       Date:  2018-01-01       Impact factor: 2.911

3.  Serum osteoprotegerin as a biomarker for vascular disease.

Authors:  Ann Van Campenhout; Paula Clancy; Jonathan Golledge
Journal:  Am J Cardiol       Date:  2007-06-06       Impact factor: 2.778

4.  Interactions between smoking, pulmonary surfactant protein B, and atherosclerosis in the general population: the Dallas Heart Study.

Authors:  Ann B Nguyen; Anand Rohatgi; Christine K Garcia; Colby R Ayers; Sandeep R Das; Susan G Lakoski; Jarett D Berry; Amit Khera; Darren K McGuire; James A de Lemos
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-08-04       Impact factor: 8.311

5.  Differential associations between soluble cellular adhesion molecules and atherosclerosis in the Dallas Heart Study: a distinct role for soluble endothelial cell-selective adhesion molecule.

Authors:  Anand Rohatgi; Andrew W Owens; Amit Khera; Colby R Ayers; Kamakki Banks; Sandeep R Das; Jarett D Berry; Darren K McGuire; James A de Lemos
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-10       Impact factor: 8.311

6.  Sex differences in the relationship between C-reactive protein and body fat.

Authors:  Amit Khera; Gloria L Vega; Sandeep R Das; Colby Ayers; Darren K McGuire; Scott M Grundy; James A de Lemos
Journal:  J Clin Endocrinol Metab       Date:  2009-06-30       Impact factor: 5.958

7.  Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality.

Authors:  Wolfgang Lieb; Philimon Gona; Martin G Larson; Joseph M Massaro; Izabella Lipinska; John F Keaney; Jian Rong; Diane Corey; Udo Hoffmann; Caroline S Fox; Ramachandran S Vasan; Emelia J Benjamin; Christopher J O'Donnell; Sekar Kathiresan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-05-06       Impact factor: 8.311

8.  Plasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk.

Authors:  Dorette Raaz-Schrauder; Michael G Schrauder; Christian Stumpf; Piotr Lewczuk; Tobias Kilian; Barbara Dietel; Christoph D Garlichs; Christian Schlundt; Stephan Achenbach; Lutz Klinghammer
Journal:  Heart Vessels       Date:  2017-05-31       Impact factor: 2.037

9.  Receptor activator of nuclear factor-κB ligand (RANKL) and its relationship to coronary atherosclerosis in HIV patients.

Authors:  Janice J Hwang; Jeffrey Wei; Suhny Abbara; Steven K Grinspoon; Janet Lo
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

10.  Elevated osteoprotegerin is associated with abnormal ankle brachial indices in patients infected with HIV: a cross-sectional study.

Authors:  James J Jang; Aron I Schwarcz; Daniel A Amaez; Mark Woodward; Jeffrey W Olin; Marla J Keller; Alison D Schecter
Journal:  J Int AIDS Soc       Date:  2010-03-22       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.